OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Integrating Novel Therapies into Treatment of B-Cell Malignancies

home / insights / b-cell-malignancies
Changing Treatment Landscape in CLL

EP. 1: Changing Treatment Landscape in CLL

June 30th 2015
Role of B-Cell Receptor Signaling Inhibitors in CLL

EP. 2: Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015
Preventing Infusion Reactions With CD20 Antibodies in CLL

EP. 3: Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015
Ibrutinib Monotherapy and Combinations in CLL

EP. 4: Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015
Ibrutinib-Associated Adverse Events

EP. 5: Ibrutinib-Associated Adverse Events

June 30th 2015
Emerging Strategies in CLL and Follicular Lymphoma

EP. 6: Emerging Strategies in CLL and Follicular Lymphoma

June 30th 2015
B-Cell Receptor Inhibitor Response Criteria in CLL

EP. 7: B-Cell Receptor Inhibitor Response Criteria in CLL

June 30th 2015
Ibrutinib in Waldenström's Macroglobulinemia

EP. 8: Ibrutinib in Waldenström's Macroglobulinemia

June 30th 2015
Frontline Treatments for Follicular Lymphoma

EP. 9: Frontline Treatments for Follicular Lymphoma

June 30th 2015
Stem Cell Transplantation in Follicular Lymphoma

EP. 10: Stem Cell Transplantation in Follicular Lymphoma

June 30th 2015
Management of Refractory Follicular Lymphoma

EP. 11: Management of Refractory Follicular Lymphoma

June 30th 2015
Diffuse Large B-Cell Lymphoma Treatment Regimens

EP. 12: Diffuse Large B-Cell Lymphoma Treatment Regimens

June 30th 2015
Treating Relapsed Diffuse Large B-Cell Lymphoma

EP. 13: Treating Relapsed Diffuse Large B-Cell Lymphoma

June 30th 2015
Upfront Treatments for Mantle Cell Lymphoma

EP. 14: Upfront Treatments for Mantle Cell Lymphoma

June 30th 2015
Treatments for Relapsed Mantle Cell Lymphoma

EP. 15: Treatments for Relapsed Mantle Cell Lymphoma

June 30th 2015
Non-Intensive Treatments for Mantle Cell Lymphoma

EP. 16: Non-Intensive Treatments for Mantle Cell Lymphoma

June 30th 2015

Latest Conference Coverage

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact